RE: Morning16 Jun 2018 11:11
Hi Ruck, we do not need to, understand the science of every drug in development, because we can only trial against current standard of care. So the only winner at any one moment is "the current standard of care"
Immunobody works in synergy with it ...
I think you have to reason your post way further to generate a risk factor, because in fairness the trial process is transparent, so we can see data on drugs at phase 2 which would indicate a "wow" factor at least 3 years before approval, subject of course to that data maintaining in a big phase 3 trial.
Nobody is judging other investments of the individual, but that does not mean we cannot analyse specific data contained in those investments, after all that is what we all do even if you chose other stocks.
we have been tracking this area now for years, has something that you have found caught your attention ..? maybe you could let us in on the science.
appreciate its all about making money, and even bad stocks can get an unrealistic ramp up.